Perioperative Management of Thalidomide

Perioperative Discontinuation Guidelines

The American College of Rheumatology recommends that thalidomide should be stopped 7 days before elective surgery to minimize bleeding risk and potential complications, allowing for complete elimination of the drug and its effects 1
For high bleeding risk procedures, such as neurosurgery, cardiac surgery, and major vascular surgery, thalidomide should be stopped 7 days before surgery and resumed no earlier than 48-72 hours after surgery when hemostasis is assured, as recommended by the American College of Chest Physicians 2
For low-to-moderate bleeding risk procedures, thalidomide should be stopped 7 days before surgery and may be resumed within 24 hours after surgery if adequate hemostasis is achieved, as recommended by the American College of Chest Physicians 2

Patients with renal impairment may require longer discontinuation periods due to potential altered drug clearance, as reported in the journal Blood 4

Thalidomide should be resumed no earlier than 24 hours after low bleeding risk procedures, and 48-72 hours after high bleeding risk procedures, with confirmation of adequate hemostasis, as recommended by the American College of Chest Physicians 2

Patients should be monitored for signs of bleeding or poor wound healing in the immediate postoperative period, as recommended by the American College of Surgeons 3